Evidence map›Paper›PMID 31449183›Full record

ArticleTransplantation2020

Further Evidence That the Soluble Urokinase Plasminogen Activator Receptor Does Not Directly Injure Mice or Human Podocytes.

Efrat Harel, Jun Shoji, Vivek Abraham, Loan Miller, Zoltan G Laszik, Andrew King, Dejan Dobi, Gyula Szabo, Byron Hann, Minnie M Sarwal and 2 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplantation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Precision medicine for focal segmental glomerulosclerosis.Kidney research and clinical practice · 2024
    Article
  6. Review
  7. Article
  8. suPAR: An Inflammatory Mediator for Kidneys.Kidney diseases (Basel, Switzerland) · 2022
    Review
  9. Review
  10. Biomarkers in pediatric glomerulonephritis and nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 2021
    Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Efrat HarelDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA.
Jun ShojiKidney Transplant Service, University of California, San Francisco, CA.
Vivek AbrahamAbbVie, Renal Discovery, Chicago, IL.
Loan MillerAbbVie, Renal Discovery, Chicago, IL.
Zoltan G LaszikKidney Transplant Service, University of California, San Francisco, CA.
Andrew KingAbbVie, Renal Discovery, Chicago, IL.
Dejan DobiKidney Transplant Service, University of California, San Francisco, CA.
Gyula SzaboKidney Transplant Service, University of California, San Francisco, CA.
Byron HannHelen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA.
Minnie M SarwalDivision of Transplant Surgery, University of California San Francisco, San Francisco, CA.
Charles S CraikDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA.
Flavio VincentiKidney Transplant Service, University of California, San Francisco, CA.
University of California, San Francisco · US

Funding

Translational InformaticsP30CA082103 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kate Taylor Shumate · 1999 to 2026
$209.7M
Renewable antibodies to secreted proteins and single and multi-pass cell surfaceP41CA196276 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MARKS, JAMES D. · 2014 to 2018
$5.8M
The KIDCOV Study: Assessment of Kidney Injury and Associated Risk Factors for SARS-CoV-2R01DK109720 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI REISER, JOCHEN, SARWAL, MINNIE M · 2017 to 2021
$3.2M
NCI NIH HHS P30 CA082103NCI NIH HHS P41 CA196276NIDDK NIH HHS R01 DK109720
6 · The paper itself

Abstract

backgroundThe role of the soluble urokinase plasminogen activator receptor (suPAR) in focal segmental glomerulosclerosis (FSGS) as the circulating factor or as a predictor of recurrence after transplantation remains controversial. Previously published studies in mice and isolated podocytes produced conflicting results on the effect of suPAR on podocyte injury, effacement of foot processes, and proteinuria. These discordant results were in part due to diverse experimental designs and different strains of mice. The aim of our study was to determine the reasons for the inconsistencies of the previous studies results with suPAR by using uniform methods and studies in different strains of mice.

methodsWe utilized a primary culture of human podocytes and 2 mouse models, the wild type (WT) and the urokinase plasminogen activator receptor (uPAR) KO (uPAR), in an attempt to resolve the reported conflicting results.

resultsIn both WT and uPAR mouse models, injection of recombinant uPAR, even at a high dose (100 μg), did not induce proteinuria, effacement of podocytes, or disruption of the cytoskeleton. Injection of suPAR resulted in its deposition exclusively in the glomerular endothelial cells and not in the podocytes of WT mice and was not detected at the uPAR KO mice. Kidneys from patients with recurrent FSGS had negative immunostaining for uPAR. We also evaluated the effect of recombinant uPAR on primary culture of human podocytes. uPAR did not result in podocytes damage.

conclusionssuPAR by itself is not the cause for direct podocyte injury, in vitro or in vivo. These findings suggest a more complex and still poorly understood role of suPAR in FSGS.

Indexed as

AnimalsAutoantibodiesBiopsyCD40 AntigensCells, CulturedGlomerulosclerosis, Focal SegmentalHumansKidneyMiceMice, KnockoutPodocytesPrimary Cell CultureReceptors, Urokinase Plasminogen ActivatorRecombinant ProteinsAutoantibodiesCD40 AntigensPLAUR protein, humanPlaur protein, mouseReceptors, Urokinase Plasminogen ActivatorRecombinant Proteins

Identifiers

PMID31449183
PMCPMC6933079
OpenAlexW2969866140

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.